Characterization of the postjunctional α 2C-adrenoceptor mediating vasoconstriction to UK14304 in porcine pulmonary veins

British Journal of Pharmacology

Volumn 151, Issue 2, 2007, Pages 186-194

  Gornemann T ^a   Von Wenckstern, H ^a   Kleuser, B ^a   Villalon C M ^b   Centurion D ^b   Jahnichen S ^a,c   Pertz, H H ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b Cinvestav SedeSur   (Mexico)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

adrenoceptor antagonists; 2 adrenoceptors; Porcine pulmonary veins; UK14304; Vasoconstriction

Indexed keywords

1,3,4,5',6,6',7,12B OCTAHYDRO 1',3' DIMETHYL 2H SPIRO[BENZO[B]FURO[2,3 A]QUINOLIZINE 2,4' PYRIMIDINE] 2' ONE; 2 (1 METHYL 2 ISOINDOLINYLMETHYL) 2 IMIDAZOLINE; 2 [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] 4,4 DIMETHYL 1,3(2H,4H) ISOQUINOLINEDIONE; 2 [[2 (2,6 DIMETHOXYPHENOXY)ETHYL]AMINOMETHYL] 1,4 BENZODIOXAN; ALPHA 2A ADRENERGIC RECEPTOR; ALPHA 2C ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BRIMONIDINE; CLONIDINE; MESSENGER RNA; NORADRENALIN; PHENYLEPHRINE; PRAZOSIN; RADIOLIGAND; RAUWOLSCINE; YOHIMBINE;

ANIMAL TISSUE; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; LIGAND BINDING; NONHUMAN; NUCLEOTIDE SEQUENCE; POSTSYNAPTIC MEMBRANE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY VEIN; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SWINE; VASOCONSTRICTION;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; CLONIDINE; DIOXANES; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; IMIDAZOLES; INDOLES; ISOQUINOLINES; NEUROMUSCULAR JUNCTION; NOREPINEPHRINE; PIPERAZINES; PRAZOSIN; PULMONARY VEINS; QUINOLIZINES; QUINOXALINES; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, ADRENERGIC, ALPHA-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SWINE; VASOCONSTRICTION; YOHIMBINE;

EID: 34248561032     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707221     Document Type: Article

References (39)

1. Arunlakshana O, Schild HO (1959). Some quantitative uses of drug antagonists. Br J Pharmacol 14: 48-58.
2. Blaylock NA, Wilson VG (1995). Pharmacological characterization of noradrenaline-induced contractions of the porcine isolated palmar lateral vein and palmar common digital artery. Br J Pharmacol 114: 694-702.
3. Bockman CS, Jeffries WB, Abel PW (1993). Binding and functional characterization of alpha-2 adrenergic receptor subtypes on pig vascular endothelium. J Pharmacol Exp Ther 267: 1126-1133.
4. Bylund DB, Eikenberg DC, Hieble JP, Langer SZ, Lefkowitz RJ, Minneman KP et al. (1994). International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev 46: 121-136.
5. Bylund DB, Ray-Prenger C, Murphy TJ (1988). Alpha-2A and alpha-2B adrenergic receptor subtypes: antagonist binding in tissues and cell lines containing only one subtype. J Pharmacol Exp Ther 245: 600-607.
6. 2-agonist for the characterisation of a-adrenoceptor subtypes. Eur J Pharmacol 72: 413-415.
7. Chomczynski P, Sacchi N (1987). Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159.
8. Civantos Calzada B, de Artiñano A (2001). Alpha-adrenoceptor subtypes. Pharmacol Res 44: 195-208.
9. 2-adrenoceptor agonists as nasal decongestants. Pulm Pharmacol Ther 20: 149-156.
10. 2-adrenoceptor- mediated responses in pig nasal mucosa. Auton Autacoid Pharmacol 23: 208-219.
11. 2-adrenoceptors. Eur J Pharmacol 361: 1-15.
12. Furchgott RF (1972). The classification of adrenoceptors (adrenergic receptors). An evaluation from the standpoint of receptor theory. In: Blaschko H and Muscholl E (eds). Catecholamines, Handbook of Experimental Pharmacology, Vol 33. Springer: Berlin, Heidelberg, New York, pp 283-335.
13. 2C-Adrenoceptors mediate contractile responses to noradrenaline in the human saphenous vein. Naunyn-Schmiedebergs Arch Pharmacol 355: 406-411.
14. Guimarães S, Moura D (2001). Vascular adrenoceptors: an update. Pharmacol Rev 53: 319-356.
15. Hoyer D, Boddeke HWGM (1993). Partial agonists, full agonists, antagonists: dilemmas of definition. Trends Pharmacol Sci 14: 270-275.
16. Hyman AL, Kadowitz PJ (1985). Evidence for existence of postjunctional alpha-1 and alpha-2 adrenoceptors in cat pulmonary vascular bed. Am J Physiol 249: H891-H898.
17. Hyman AL, Kadowitz PJ (1986). Enhancement of α- and β-adrenoceptor responses by elevations in vascular tone in pulmonary circulation. Am J Physiol 250: H1109-H1116.
18. Jenkinson DH, Barnard EA, Hoyer D, Humphrey PPA, Leff P, Shankley NP (1995). International union of pharmacology committee on receptor nomenclature and drug classification: IX. Recommendations on terms and symbols in quantitative pharmacology. Pharmacol Rev 47: 255-266.
19. Kenakin T (1993). Pharmacologic Analysis of Drug-Receptor- Interaction, 2nd edn. Raven Press: New York.
20. 2A subtype. Br J Pharmacol 121: 1721-1729.
21. Ohlstein EH, Horohonich S, Shebuski RJ, Ruffolo Jr RR (1989). Localization and characterization of alpha-2 adrenoceptors in the isolated canine pulmonary vein. J Pharmacol Exp Ther 248: 233-239.
22. 2-adrenoceptors of the dog mesenteric and rat femoral veins. Naunyn-Schmiedebergs Arch Pharmacol 360: 165-170.
23. Piascik MT, Guarino RD, Smith MS, Soltis EE, Saussy DL, Perez DM (1995). The specific contribution of the novel alpha-1D adrenoceptor to the contraction of vascular smooth muscle. J Pharmacol Exp Ther 275: 1583-1589.
24. Platt JL (2001). Xenotransplantation. ASM Press: Washington, DC.
25. Pound WJ, Houpt KA (1978). The pig as a model in biomedical research. In: Pond WG (ed). The Biology of the Pig. Comstock Publishing Associates, Cornell University Press: Ithaca, NY, pp 13-64.
26. Rozen S, Skaletsky HJ (2000). Primer3 on the WWWfor general users and for biologist programmers. In: Krawetz S and Misener S (eds). Bioinformatics Methods and Protocols: Methods in Molecular Biology. Humana Press: Totowa NJ, pp 365-386. Source code available at http://fokker.wi.mit.edu/primer3/.
27. 2-adrenergic receptor subtypes in cells and tissues. Pharmacol Ther 84: 193-205.
28. Shebuski RJ, Ohlstein EH, Smith Jr JM, Ruffolo Jr RR (1987). Enhanced pulmonary alpha-2 adrenoceptor responsiveness under conditions of elevated pulmonary vascular tone. J Pharmacol Exp Ther 242: 158-165.
29. Shebuski RJ, Fujita T, Ruffolo Jr RR (1986). Evaluation of alpha-1 and alpha-2 adrenoceptor-mediated vasoconstriction in the in situ, autoperfused pulmonary circulation of the anaesthetized dog. J Pharmacol Exp Ther 238: 217-223.
30. Trendelenburg AU, Sutej I,Wahl CA, Molderings GJ, Rump LC, Starke K (1997). A re-investigation of questionable subclassifications of presynaptic alpha2-autoreceptors: rat vena cava, rat atria, human kidney and guinea-pig urethra. Naunyn Schmiedebergs Arch Pharmacol 356: 721-737.
31. Uhlén S, Porter AC, Neubig RR (1994). The novel alpha-2 adrenergic radioligand [3H]-MK912 is alpha-2C selective among human alpha-2A, alpha-2B and alpha-2C adrenoceptors. J Pharmacol Exp Ther 271: 1558-1565.
32. 2-adrenoceptor. Br J Pharmacol 106: 986-995.
33. Van Rossum JM (1963). Cumulative dose-response curves. II. Technique for making dose-response curves in isolated organs and the evaluation of drug parameters. Arch Int Pharmacodyn Ther 143: 299-330.
34. 2A- adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries. Invest Ophthalmol Vis Sci 42: 2049-2055.
35. 2C-adrenoceptors in the pig cerebellum and kidney cortex. Eur J Pharmacol 284: 271-279.
36. 2-adrenoceptor subtypes mediating vasoconstriction in the canine external carotid circulation. Br J Pharmacol 132: 1292-1298.
37. Willems EW, Valdivia LF, Saxena PR, Villalón CM (2001b). Pharmacological profile of the mechanisms involved in the external carotid vascular effects of the antimigraine agent isometheptene in anaesthetised dogs. Naunyn-Schmiedebergs Arch Pharmacol 364: 27-32.
38. Wright IK, Blaylock NA, Kendall DA, Wilson VG (1995). The relationship between density of alpha-adrenoceptor binding sites and contractile responses in several porcine isolated blood vessels. Br J Pharmacol 114: 678-688.
39. 2B-adrenoceptor subtypes. Eur J Pharmacol 168: 381-386.